New mpox vaccine trial launches in DRC: could it be a game changer?
NCT ID NCT07253675
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 study will test a new mpox vaccine called MVA-SIBP in 180 people aged 2 to 45 in Kinshasa, DRC. Participants will receive two doses of either a low or high dose of the new vaccine, or a licensed vaccine (MVA-BN) for comparison. The goal is to check safety and how well the vaccine triggers an immune response against mpox.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MVA-SIBP vaccine (low and high dose) compared to MVA-BN vaccine
- What this could lead to
- If successful, this could provide a new, locally produced mpox vaccine for use in the Democratic Republic of the Congo and other affected regions.
- What could go wrong
- This is a Phase 2 trial with only 180 participants, so results may not apply to larger populations. The vaccine may not produce strong enough immunity or could cause unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MONKEYPOX (MPOX) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.